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To the Editor: Vismodegib is a small molecule inhi-
bitor of SMO (smoothened), a transcription gene
present in the hedgehog signalingmolecule pathway
and implicated in the proliferation of basal cell
carcinomas (BCCs).1 In January 2012, vismodegib
was approved by the Food and Drug Administration
for the treatment in adults with metastatic BCCs,
for the treatment of locally advanced BCCs that
recurred following surgery, and in patients who are
not candidates for surgery and/or radiation.
Vismodegib is an ineffective treatment for cutaneous
squamous cell carcinomas (SCCs). The use of vismo-
degib for the treatment of BCCs with concurrent
adjuvant radiotherapy for the treatment of SCCs has
not been previously reported in the literature. We
report a case of numerous BCCs and progressive
SCCs, successfully treated with vismodegib and
concurrent external beam radiation, respectively.
An 81-year-old Caucasian man presented with
multiple ulcerative and exophytic lesions on his face,
trunk, and extremities that were concerning for
locally invasive nonmelanoma skin cancers. The
patient had similarly concerning but less extensive
lesions 2 years earlier but declined treatment and
was subsequently lost to follow-up. In the interim,
because of progressive dementia, the Department of
Social Services assigned him a guardian.
Open access under CC BY-NC-ND license.On exam, the patient had evidence of numerous
extensive tumors of the face, trunk, and extremities
(Fig 1). Consults with dermatologic surgery and
plastic surgery specialists deemed that it was not
feasible to remove all the lesions or treat them with
radiation given their extensive number and severity.
Palliation andhospicewere recommended. In follow-
up, progressive ectropion of the bilateral eyelids with
resultant exposure keratopathy developed, and the
ulcerative lesions on the face, trunk, and extremities
worsened (Fig 1). After discussion with the patient’s
guardian, the patient was started on vismodegib 150
mg daily oral therapy in August 2012. At the patient’s
10-week follow-up, many of the tumors had almost
completely resolved; however, lesions on the left
parietal scalp, left zygoma, and left lower leg showed
evidence of progression. Subsequent biopsies were
consistent with invasive SCCs.
The patient was referred to radiation oncology for
possible radiotherapy. Over the next 7 weeks, the
patient received 60 Gy (intensity modulated radia-
tion therapy technique) and 40/48 Gy (en face
electrons) to the left parietal scalp and left zygoma.
At the patient’s most recent follow-up in August
2013, most of the tumor burden from his BCCs had
Fig 1. Darier disease, patient 1. Pretreatment (A) and
following application of diclofenac sodium 3% gel twice
daily for 8 months (B).
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plaques (Fig 2). The SCC on the left zygoma had
shrunken significantly enough to allow the patient to
become a candidate for surgical repair of his
ectropion (Fig 2).
Our case illustrates that SCCs that emerge while
on vismodegib for BCCs can be successfully and
concurrently treated with external beam radiation.
Standard doses for SCC were given over a 7-week
timeframe with good response. This finding is
particularly pertinent given the recently reported
observation of SCC emergence after vismodegib
treatment.2,3 Further studies are needed to assess
this potential complication of vismodegib therapy;
however, for those patients on vismodegib who
experience progressive locally invasive SCCs not
amenable to surgical intervention, external beam
radiation remains a viable treatment option.
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Improvement of Darier disease with
diclofenac sodium 3% gel
To the Editor: Darier disease (DD) is an uncommon
autosomal dominant disorder with complete pene-
trance and variable expressivity. The responsible
gene has been mapped to the 12q23-q24.1 chromo-
some region.1 This gene codifies ATP2A2, which
encodes a sarcoplasmic/endoplasmic reticulum
calcium-ATPase, SERCA2, involved in epidermaldifferentiation and intercellular communication.
Treatments for DD include topical retinoids, calcipo-
triene, and 5-fluorouracil, dermabrasion, photody-
namic therapy, laser abrasion, and oral retinoids. We
present 2 cases of DD that responded to topical 3%
diclofenac sodium 3% gel.
Patient 1 was a 63-year-old man, with no relevant
medical or family background, diagnosed with DD
based on the typical clinical and histopathologic
findings. When he suffered an exacerbation of DD
that did not respond to conventional therapies,
diclofenac sodium 3% in hyaluronic acid 2.5%
(Solaraze) was applied twice daily to the left back
and the sacral area (Fig 1, A).
After 8 months of treatment, there was a marked
improvement (Fig 1, B). Only a few lesions remained
in the sacral area, therefore treatment of that areawas
continued for 1 year.
Patient 2 was a 37-year-old woman with DD
diagnosed at 18 years of age. Her mother had
psoriasis and DD. Treatment with topical therapies
and oral retinoids had been unsuccessful. Based on
the response observed in patient 1, diclofenac so-
dium 3% gel applied twice daily to the left shoulder
and right side of the neck was prescribed (Fig 2, A).
After 3 months of treatment, the DD lesions almost
completely resolved at both sites (Fig 2, B). There
was some recurrence of skin lesions 3 months after
diclofenac was discontinued.
We noted resolution of lesions beyond the appli-
cation sites of the gel in both cases. The topical
treatment was well tolerated, although patient 2 did
complain of irritation on the neck after application.
Ultraviolet (UV) B radiation is known to stimulate
the cyclooxygenase-2 (COX-2) pathway within ker-
atinocytes. This increases the production of prosta-
glandin E2 and reduces the expression of ATP2A2
